Management of imatinib-related exacerbation of psoriasis in a patient with a gastrointestinal stromal tumour

Australasian Journal of Dermatology

Volumn 50, Issue 1, 2009, Pages 41-43

  Cheng, Haiying ^a   Geist, David E ^a   Piperdi, May ^a   Virk, Renu ^a   Piperdi, Bilal ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Methotrexate; Tyrosine kinase inhibitors

Indexed keywords

FLUOCINONIDE; FOLIC ACID; IMATINIB; METHOTREXATE; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR; TRIAMCINOLONE;

ABDOMINAL MASS; ABDOMINAL SURGERY; ADULT; ARTICLE; BLOOD EXAMINATION; CASE REPORT; CAUCASIAN; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HUMAN TISSUE; PELVIS LYMPH NODE; PHOTOTHERAPY; PSORIASIS; RECURRENT DISEASE; SKIN BIOPSY; TUMOR VOLUME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ERUPTIONS; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; METHOTREXATE; MIDDLE AGED; PERITONEAL NEOPLASMS; PIPERAZINES; PSORIASIS; PYRIMIDINES; TREATMENT OUTCOME;

EID: 58249096084     PISSN: 00048380     EISSN: 14400960     Source Type: Journal    
DOI: 10.1111/j.1440-0960.2008.00495.x     Document Type: Article

References (10)

1. Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumour. Lancet 2007 369 : 1731 41.
2. Scheinfeld N. Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate. J. Drugs Dermatol. 2006 5 : 228 31.
3. Heidary N, Naik H, Burgin S. Chemotherapeutic agents and the skin: An update. J. Am. Acad. Dermatol. 2008 58 : 545 70.
4. Miyagawa S, Fujimoto H, Ko S, Hirota S, Kitamura Y. Improvement of psoriasis during imatinib therapy in a patient with a metastatic gastrointestinal stromal tumour. Br. J. Dermatol. 2002 147 : 406 7.
5. Paniagua RT, Robinson WH. Imatinib for the treatment of rheumatic diseases. Nat. Clin. Pract. Rheumatol. 2007 3 : 190 1.
6. Wolf D, Tilg H, Rumpold H, Gastl G, Wolf AM. The kinase inhibitor imatinib-an immunosuppressive drug? Curr. Cancer Drug Targets 2007 7 : 251 8.
7. Mohty M, Blaise D, Olive D, Gaugler B. Imatinib: the narrow line between immune tolerance and activation. Trends Mol. Med. 2005 11 : 397 402.
8. Woo SM, Huh CH, Park KC, Youn SW. Exacerbation of psoriasis in a chronic myelogenous leukemia patient treated with imatinib. J. Dermatol. 2007 34 : 724 6.
9. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007 445 : 866 73.
10. Collamer AN, Guerrero KT, Henning JS, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum. 2008 59 : 996 1001.